miR‑126 regulates the progression of epithelial ovarian cancer in vitro and in vivo by targeting VEGF‑A

Liu,Lin; Yuan,Li; Huang,Da; Han,Qing; Cai,Jing; Wang,Shaohai; Cao,Jin

doi:10.3892/ijo.2020.5082

miR‑126 regulates the progression of epithelial ovarian cancer in vitro and in vivo by targeting VEGF‑A

Authors:
- Lin Liu
- Li Yuan
- Da Huang
- Qing Han
- Jing Cai
- Shaohai Wang
- Jin Cao
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Obstetrics and Gynecology, The First People's Hospital of Shangqiu, Shangqiu, Henan 476100, P.R. China, Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: June 16, 2020 https://doi.org/10.3892/ijo.2020.5082
Pages: 825-834

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miRNA/miR‑126) has been shown to be associated with ovarian cancer in previous studies. In ovarian cancer, however, the specific status of miR‑126 remains largely unknown. In the present study, to clarify its role in ovarian cancer, the levels of miR‑126 were first examined using laser microdissection and RT‑qPCR. It was found that the miR‑126 level was decreased in ovarian tissue samples and the restoration of miR‑126 inhibited cell proliferation, cell invasion and migration in vitro and suppressed tumor growth in vivo. A bioinformatics search revealed that the angiogenesis‑related gene, vascular endothelial growth factor (VEGF)‑A, was among the potential targets of miR‑126. The suppression of invasion and proliferation induced by ectopic miR‑126 expression was nullified by the ectopic expression of VEGF‑A, suggesting that these suppressive effects were largely attributable to the ability of miR‑126 to target VEGF‑A. Moreover, the restoration of miR‑126 suppressed the angiogenic potential of human umbilical vein endothelial cells (HUVECs). On the whole, these findings indicate that the loss of expression of miR‑126 contributes to the abnormal VEGF‑A accumulation and subsequent unchecked cell invasion and cell proliferation in epithelial ovarian cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Meister J and Schmidt MHH: miR-126 and miR-126^*: New players in cancer. ScientificWorldJournal. 10:2090–2100. 2010. View Article : Google Scholar : PubMed/NCBI
3	Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D: miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 15:272–284. 2008. View Article : Google Scholar : PubMed/NCBI
4	Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, et al: miR-126 and miR-126^* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol. 15:284–294. 2013. View Article : Google Scholar : PubMed/NCBI
5	Ebrahimi F, Gopalan V, Smith RA and Lam AK: miR-126 in human cancers: Clinical roles and current perspectives. Exp Mol Pathol. 96:98–107. 2014. View Article : Google Scholar
6	Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R and Olson EN: The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 15:261–271. 2008. View Article : Google Scholar : PubMed/NCBI
7	Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W and Tuschl T: Identification of tissue-specific microRNAs from mouse. Curr Biol. 12:735–739. 2002. View Article : Google Scholar : PubMed/NCBI
8	Roviello G, Bachelot T, Hudis CA, Curigliano G, Reynolds AR, Petrioli R and Generali D: The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. Eur J Cancer. 75:245–258. 2017. View Article : Google Scholar : PubMed/NCBI
9	Pan C, Stevic I, Müller V, Ni Q, Oliveira-Ferrer L, Pantel K and Schwarzenbach H: Exosomal microRNAs as tumor markers in epithelial ovarian cancer. Mol Oncol. 12:1935–1948. 2018. View Article : Google Scholar : PubMed/NCBI
10	Prahm KP, Høgdall C, Karlsen MA, Christensen IJ, Novotny GW and Høgdall E: Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. PLoS One. 13:e02073192018. View Article : Google Scholar : PubMed/NCBI
11	Wu G, Cao L, Zhu J, Tan Z, Tang M, Li Z, Hu Y, Yu R, Zhang S, Song L, et al: Loss of RBMS3 confers platinum resistance in epithelial ovarian cancer via activation of miR-126-5p/ β-catenin/CBP signaling. Clin Cancer Res. 25:1022–1035. 2019. View Article : Google Scholar
12	Xiang G and Cheng Y: MiR-126-3p inhibits ovarian cancer proliferation and invasion via targeting PLXNB2. Reprod Biol. 18:218–224. 2018. View Article : Google Scholar : PubMed/NCBI
13	Luo P, Fei J, Zhou J and Zhang W: microRNA-126 suppresses PAK4 expression in ovarian cancer SKOV3 cells. Oncol Lett. 9:2225–2229. 2015. View Article : Google Scholar : PubMed/NCBI
14	Cai J, Li T, Huang B, Cheng H, Ding H, Dong W, Xiao M, Liu L and Wang Z: The use of laser microdissection in the identification of suitable reference genes for normalization of quantitative real-time PCR in human FFPE epithelial ovarian tissue samples. PLoS One. 9:e959742014. View Article : Google Scholar : PubMed/NCBI
15	Xie H, Zou L, Zhu J and Yang Y: Effects of netrin-1 and netrin-1 knockdown on human umbilical vein endothelial cells and angio-genesis of rat placenta. Placenta. 32:546–553. 2011. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
17	Li Q, Cheng K, Wang AY, Xu QG, Fu ZF, He SY and Xu PX: microRNA-126 inhibits tube formation of HUVECs by interacting with EGFL7 and down-regulating PI3K/AKT signaling pathway. Biomed Pharmacother. 116:1090072019. View Article : Google Scholar : PubMed/NCBI
18	Guo J, Cai J, Yu L, Tang H, Chen C and Wang Z: EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Sci. 102:530–539. 2011. View Article : Google Scholar : PubMed/NCBI
19	Bu J, Li H, Li XY, Liu LH, Sun W and Xiao T: Prognostic role of microRNA-126 for survival in malignant tumors: A systematic review and meta-analysis. Dis Markers. 2015:7394692015. View Article : Google Scholar : PubMed/NCBI
20	Gu L, Li H, Chen L, Ma X, Gao Y, Li X, Zhang Y, Fan Y and Zhang X: MicroRNAs as prognostic molecular signatures in renal cell carcinoma: A systematic review and meta-analysis. Oncotarget. 6:32545–32560. 2015. View Article : Google Scholar : PubMed/NCBI
21	Luo J, Zhu C, Wang H, Yu L and Zhou J: MicroRNA-126 affects ovarian cancer cell differentiation and invasion by modulating expression of vascular endothelial growth factor. Oncol Lett. 15:5803–5808. 2018.PubMed/NCBI
22	Chen H, Li L, Wang S, Lei Y, Ge Q, Lv N, Zhou X and Chen C: Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A. Oncotarget. 5:11873–11885. 2014. View Article : Google Scholar : PubMed/NCBI
23	Chen CY, Su CM, Hsu CJ, Huang CC, Wang SW, Liu SC, Chen WC, Fuh LJ and Tang CH: CCN1 promotes VEGF production in osteoblasts and induces endothelial progenitor cell angiogenesis by inhibiting miR-126 expression in rheumatoid arthritis. J Bone Miner Res. 32:34–45. 2017. View Article : Google Scholar
24	Kong D, Ying B, Zhang J and Ying H: The anti-osteosarcoma property of ailanthone through regulation of miR-126/VEGF-A axis. Artif Cells Nanomed Biotechnol. 47:3913–3919. 2019. View Article : Google Scholar : PubMed/NCBI
25	Liu B, Peng XC, Zheng XL, Wang J and Qin YW: MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer. 66:169–175. 2009. View Article : Google Scholar : PubMed/NCBI
26	Caporali S, Amaro A, Levati L, Alvino E, Lacal PM, Mastroeni S, Ruffini F, Bonmassar L, Antonini Cappellini GC, Felli N, et al: miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A. J Exp Clin Cancer Res. 38:2722019. View Article : Google Scholar : PubMed/NCBI
27	Cortez AJ, Tudrej P, Kujawa KA and Lisowska KM: Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 81:17–38. 2018. View Article : Google Scholar :
28	Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 32:1302–1308. 2014. View Article : Google Scholar : PubMed/NCBI